Amgen builds its digital health capabilities through investment in leading digital health incubator

AmgenAmgen (Europe) GmbH, an affiliate of Amgen Inc. (NASDAQ:AMGN) (collectively, "Amgen") today announced an investment in eHealth Ventures, an Israel-based digital health incubator. The investment reflects Amgen's commitment to serving patients by driving innovation and sustainable healthcare through technology discovery, and recognizes the importance of Israel as a source of innovation in eHealth and digital technologies. Additional investors include Israeli HMO Maccabi Healthcare Services and Amgen's Israeli distributor Medison Pharma Ltd. Amgen will be the lead biopharmaceutical investor.

"Engaging in multi-stakeholder partnerships will drive innovation and enable us to deliver additional value to patients and the healthcare community, beyond our life-saving medicines," said Corinne Le Goff, senior vice president, Amgen Europe. "This collaboration with eHealth Ventures is a natural fit for Amgen and will help us expand our digital health pipeline and support the growth of valuable health technology to improve the lives of patients across the world."

"We are proud to have Amgen, a global market leader, join the eHealth Ventures unique consortium together with Maccabi Healthcare Services, Cleveland Clinic and Medison Pharma. This addition will provide a new strategic element to our screening process and build significant value to our portfolio companies. Having Amgen on board will deliver invaluable assets and know-how in many of the digital health innovation aspects, including market input, commercialization of R&D, business modeling, go-to-market strategies and more," said Talor Sax, eHealth Ventures Incubator chief executive officer. "We are grateful to our partner Medison Pharma, for realizing this vision and making this partnership a reality."

About eHealth Ventures
eHealth Ventures, a consortium of world-class organizations and investors active in the field of digital health, was launched in March of 2016 with Israeli government backing. The consortium, which comprises Cleveland Clinic, a leading US hospital, Maccabi Healthcare Services, Israel's leading and most advanced health provider, and Medison Pharma, Israel's largest independent specialty pharmaceutical company and Amgen's distributor in Israel, aims to invest in 40 new companies over an eight year period.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Novartis teams up with Harvard to develop next gen…

Novartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Can...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...